phenyl acetate has been researched along with Endometrial Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abd Jamil, AH; Chung, I; Mat Adenan, NA; Omar, IS | 1 |
| Bruchim, I; Flescher, E; Reiss, A; Sarfstein, R; Werner, H | 1 |
2 other study(ies) available for phenyl acetate and Endometrial Neoplasms
| Article | Year |
|---|---|
MPA alters metabolic phenotype of endometrial cancer-associated fibroblasts from obese women via IRS2 signaling.
Topics: Acetates; Cancer-Associated Fibroblasts; Endometrial Neoplasms; Female; Glucose; Humans; Insulin Receptor Substrate Proteins; Medroxyprogesterone Acetate; Mifepristone; Neoplasm Recurrence, Local; Obesity; Phenotype; Progesterone; Receptors, Progesterone; RNA, Messenger | 2022 |
IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer.
Topics: Acetates; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Dose-Response Relationship, Drug; Endometrial Neoplasms; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Oxylipins; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Time Factors | 2014 |